

Good morning,

I am writing to appeal to the committee to consider allowing the use of cyproheptadine as a preferred agent in pediatric patients as an appetite stimulant. In our practice it is our preference to use cyproheptadine over megestrol due to the steroid component of megestrol and its potential impact on the oncology population. Dronabinol is typically our second line agent. Cyproheptadine has good evidence for this indication with minimal side effects, thus our preference to use it. Cyproheptadine, however, is a non-preferred agent in the antihistamine category and we would like to request it be allowed as a preferred agent for the indication of appetite stimulant in pediatric patients to avoid the additional work PAs cause and the potential delays in treatment as a result.

Thank you for your time,